🔴 This is an archived resource.

This resource has not been reviewed within the last three years to reflect up to date clinical guidelines and should be referenced with care.

PCRU Sponsored Supplement

Monitoring ICS underuse in asthma and over-reliance on SABA: A sponsored supplement.

Improving outcomes in asthma as an inflammatory disease: spotlight on monitoring ICS underuse and over-reliance on SABA: A sponsored supplement.

A report of a multi-disciplinary consensus meeting held in December 2018. AstraZeneca organised and fully funded the meeting and the production of this supplement. All meeting participants reviewed and commented upon the content of this supplement. The views expressed are not necessarily those of AstraZeneca or PCRS.

Asset: GB-16467
Date of preparation: April 2019

Attachment Size
SponsoredSupplementAZ_2019.pdf 3.13 MB
Clinical Area
Asthma
Category
PCRU
Listing Status
Archive
Author(s)
A consensus document; input received from D Attar-Zadeh, N Baxter, J Calvert, J Hamilton, T Harrison, M Levy, V Mak, A Murphy, W Preston, D Ryan, C Stonham, S Walker, J White. Produced by AstraZeneca